Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in the Treatment of Major Depressive Disorders
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate superior efficacy of Quetiapine fumarate
sustained release (SEROQUEL) compared with placebo when used as a mono-therapy in the
treatment of Major Depressive Disorders PLEASE NOTE: Seroquel SR and Seroquel XR refer to the
same formulation. The SR designation was changed to XR after consultation with FDA.